Changes between two versions
What changed between the draft committee report and the plenary report
From · draft committee report· 21 Mar 2025
on the future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness
To · plenary report· 1 Jul 2025
on the future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness
AI:What changed, in short
The report expands significantly, adding many new recitals and paragraphs that broaden the scope to include definitions, sector applications, regulatory reform, investment, biosecurity, and workforce issues.2346 It strengthens calls for streamlined authorisation, simplified approvals, and regulatory coordination, while also addressing feedstock access, energy costs, and strategic autonomy.3467 New provisions on IP protection, clinical trials, and AI governance are introduced, along with requests for studies and strategies on biosecurity and bioeconomy.361112 The remaining changes are mostly wording and renumbering, with some rephrasing of existing paragraphs to align with the expanded content.1579
7 changes of substance · 0 formal · 5 of wording only
Written by AI from the two texts only · read the changes before relying on it · 4 Sept 2026 · Report a problem
+57 added · −20 removed · 10 changed paragraphs, packaging included.
Part 3 of 3: EXPLANATORY STATEMENT
EXPLANATORY STATEMENT
To keep our high standard of living, our safety and future viability, Europe needs to be at the forefront of technological innovation and the EU must become world leading in research and innovation. These are the guiding principles to this report. Europe cannot succeed with its ambitions on competitiveness, decarbonisation and economic resilience without acknowledging the crucial role played by the EU’s biotechnology and biomanufacturing sector. This fascinating new science and technology transcends different industrial sectors and is based on the use of and work with living organisms, of the force of nature. It does not only enable ground-breaking innovations and manufacturing processes, it is of strategic importance in several different areas such as sustainability, economic security, food security and public health.
The growth potential of the biotechnology and biomanufacturing industry is immense and the productivity of the sector very high. The aim of this report is to shed light on the existing bottlenecks and to provide recommendations to support the industry to reach its full potential. As European lawmakers, we insist on the fact new regulation needs to be duly justified and globally connectable. The biotechnology and biomanufacturing sector encounters the general problems of other new sectors like the lack of transfer of academic knowledge to the market, insufficient access to capital and incoherent, outdated or inappropriate regulation and feedstock security. The biggest hurdle is the length of authorisation procedures in the EU giving away early-adapter advantages to competitors. There is high need to take into account the specificities of the sector also with regard to security and citizen involvement, biotechnology in terms of regulation presents a showcase for further testing regulatory sandboxes. To ensure full focus, better coordination and detectable improvements for European biotechnology and biomanufacturing companies, the creation of a Chief Biotechnology Officer in the European Commission is recommended.